Drug Topics January 13, 2025
Brian Nowosielski, Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, Ashley Gallagher

Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.

Glucagon-like peptide-1 (GLP-1) receptor agonists have proved to be the definitive standard of practice for the treatment of patients living with obesity and type 2 diabetes (T2D). However, with several variations of the medication entering the prescription drug market, it’s important for pharmacists to understand their patients’ needs and know how different GLP-1s will impact specific patient outcomes.

“Everyone is talking about tirzepatide and semaglutide, which have revolutionized the management of T2D and obesity. Tirzepatide offers very high efficacy for weight loss (more than semaglutide, based on recent evidence) most likely due to its dual mechanism, while semaglutide has established...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Interview / Q&A, Pharma / Biotech, Trends
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
CVS Caremark taps Omada on GLP-1 program
InnovationRx: Trump Administration Health Agency Layoffs Threaten Biotech Innovation
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
PBMs push private-label biosimilars in 2025 formularies

Share This Article